

ECR/784/JSS/Inst/KA/2013/Re-Registration-2022
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Ethics Committee Registration Division)

Dated:

19 MAR 2024

To,

The Chairman/Member Secretary
Institutional Ethics Committee, JSS Medical College
JSS Hospital, Mysore
JSS Medical College, Sri Shivarathreshwara Nagara,
Mysuru, Mysore, Karnataka – 570015, India

Subject: Ethics Committee Re-Registration No. **ECR/387/Inst/KA/2013/RR-22**, amendment to the composition of the Ethics Committee-regarding.

Sir/Madam,

Please refer to your application submitted to this Directorate for change in composition of the Re-Registered Ethics Committee.

Based on the documents submitted by you, the composition of your Ethics Committee bearing Registration number **ECR/387/Inst/KA/2013/RR-22** dated **13.06.2022** valid until **10.06.2027** is hereby amended as follows, with all conditions of the Registration Certificate initially granted to you, remaining the same including the condition that **“the Ethics Committee shall review and accord approval to Clinical Trial and BA/BE Study protocol of new drugs and also conduct periodic review of the studies as per the New Drugs and Clinical Trial Rules, 2019”**.

Sr. No.	Name of member	Qualification	Role/Designation in Ethics Committee
1.	Dr. M. Srinivasa	MD (General Medicine)	Chairperson
2.	Dr. Prathima.C	MBBS, MD (Pharmacology)	Member Secretary
3.	Dr. Kalabharathi L	MBBS, MD (Pharmacology)	Medical Scientist
4.	Dr. Smitha Rani	MBBS, MD (Forensic Medicine)	Medical Scientist
5.	Dr. Prathiba Pereira	MBBS, MD (General Medicine)	Clinician
6.	Dr. Srinath K.M	MBBS, MD (Internal Medicine)	Clinician
7.	Sri. Palaksha	B.Sc, LLB	Legal Expert
8.	Shri. H. N. Nithin	BBM, LLB	Legal Expert
9.	Smt. H.S. Sandhya	BA	Social Scientist
10.	Smt. Sudhaphaneesh	MA, B.Ed, PhD	Social Scientist
11.	Dr. Sathyanarayana Mamatha	B.Ed, MA, PhD	Lay Person
12.	Sri. R.S.Nagaraj	B.Sc, MA	Lay Person


13.

Dr. Harsha Chalasani

M.Pharm, PG Dip. PV, Ph.D

Scientific Member

Yours faithfully


(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

No.	Name of member	Qualification	Designation
1	Dr. M. Srinivas	MD (General Medicine)	Chairperson
2	Dr. Rajeev Singh Raghuvanshi	M.Pharm, PG Dip. PV, Ph.D	Scientific Member
3	Dr. K. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member
4	Dr. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member
5	Dr. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member
6	Dr. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member
7	Dr. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member
8	Dr. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member
9	Dr. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member
10	Dr. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member
11	Dr. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member
12	Dr. Srinivas	M.Pharm, PG Dip. PV, Ph.D	Member

File No. EC/22/000125



Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,
New Delhi - 110002, India
Dated: 13-Jun-2022

To

The Chairman
Institutional Ethics Committee, JSS Medical College
JSS Hospital, Mysore
JSS Medical College, Sri Shivarathreeshwara Nagara,
Mysuru Mysore Mysuru (Mysore) Karnataka - 570015
India

Subject: Ethics Committee Re-Registration No. ECR/387/Inst/KA/2013/RR-22 issued under New Drugs and Clinical Trials Rules, 2019.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2022/14095 dated 21-Apr-2022 submitted to this Directorate for the Re-Registration of Ethics Committee.

Please find enclosed registration of the Ethics Committee in Form CT-02 vide Registration No. ECR/387/Inst/KA/2013/RR-22. The said registration is subject to the conditions as mentioned below:-

Yours faithfully

VENUGOPAL G SOMANI
(Director General)
Central Drugs Standard Control Organization
Central Licencing Authority

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=DRUGS
CONTROL ORGANIZATION,
pseudonym=112046a34e21727mach25574
89313c, postalCode=110002, st=DELHI,
serialNumber=0974149976002405c001cf1522525
1f2d703024b49976002405c001cf282ad
eaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.06.13 18:21:21 +05'30'

Conditions of Registration

1. The registration is valid from 11-Jun-2022 to 10-Jun-2027, unless suspended or cancelled by the Central Licencing Authority.
2. This certificate is issued to you on the basis of declaration/submission made by you.
3. Composition of the said Ethics Committee is as per the Annexure.
4. No clinical trial or bioavailability or bioequivalence protocol and related documents shall be reviewed by an Ethics Committee in meeting unless at least five of its members as detailed below are present in the meeting, namely:-
 - (i) medical scientist (preferably a pharmacologist);
 - (ii) clinician;
 - (iii) legal expert;
 - (iv) social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person;

(v) lay person.

5. The Ethics Committee shall have a minimum of seven and maximum of fifteen members from medical, non-medical, scientific and non-scientific areas with at least,

(i) one lay person;

(ii) one woman member;

(iii) one legal expert;

(iv) one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.

6. One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organization and one member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.

7. The Ethics Committee shall consist of at least fifty percent of its members who are not affiliated with the institute or organization in which such committee is constituted.

8. The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.

9. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

10. Members should be conversant with the provisions of New Drug and Clinical Trials Rules, 2019, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

11. The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialization, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.

12. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

13. The Ethics Committee may associate such experts who are not its members, in its deliberations but such experts shall not have voting rights, if any

14. No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the Clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

15. While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson. The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

16. Any change in the membership or the constitution of the registered Ethics Committee shall be intimated in writing to the Central Licencing Authority within thirty working days.

17. The Ethics Committee shall review and accord approval to a Clinical trial, Bioavailability and Bioequivalence study protocol and other related documents, as the case may be, in the format specified in clause (B) of Table 1 of the Third Schedule of New Drugs and Clinical Trials Rules, 2019 and oversee the conduct of clinical trial to safeguard the rights, safety and wellbeing of trial subjects in accordance with these rules, Good Clinical Practices Guidelines and other applicable regulations.

18. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7: provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be: provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

19. Where a Bioavailability or Bioequivalence study centre does not have its own Ethics Committee, bioavailability or bioequivalence study at that site may be initiated after obtaining approval of the protocol from the Ethics Committee registered under rule 8: Provided that the approving Ethics Committee shall in such case be responsible for the study at the centre: Provided further that both the approving Ethics Committee and the centre, shall be located within the same city or within a radius of 50 kms of the bioavailability or bioequivalence study centre.

20. Ethics committee shall indicate the reasons that weighed with it while rejecting or asking for a change or notification in the protocol in writing and a copy of such reasons shall also be made available to the Central

Licencing Authority.

21. Ethics committee shall make, at appropriate intervals, an on-going review of the trials for which they have reviewed the protocol. Such a review may be based on the periodic study progress reports furnished by the investigators or monitoring and internal audit reports furnished by the sponsor or by visiting the study sites.

22. Where any serious adverse event occurs to a trial subject or to study subject during clinical trial or bioavailability or bioequivalence study, the Ethics Committee shall analyse the relevant documents pertaining to such event and forward its report to the Central Licencing Authority and comply with the provisions of Chapter VI, New Drugs and Clinical Trials Rules, 2019.

23. The Ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts wherever required, for deciding relatedness and quantum of compensation, as per condition no (22) mentioned above.

24. Where at any stage of a clinical trial, it comes to a conclusion that the trial is likely to compromise the right, safety or wellbeing of the trial subject, the Ethics committee may order discontinuation or suspension of the clinical trial and the same shall be intimated to the head of the institution conducting clinical trial and the Central Licencing Authority.

25. Ethics committee shall comply with the requirements or conditions in addition to the requirements specified under the Drugs & Cosmetics Act, 1940 and New Drugs and Clinical Trials Rues, 2019, as may be specified by the Central Licencing Authority with the approval of the Central Government, to safeguard the rights of clinical trial subject or bioavailability or bioequivalence study subject.

26. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial.

27. The Ethics Committee shall maintain data, record, registers and other documents related to the functioning and review of clinical trial or bioavailability study or bioequivalence study, as the case may be, for a period of five years after completion of such clinical trial.

28. Funding mechanism for the Ethics Committee to support their operations should be designed and approved to ensure that the committee and their members have no financial incentive to approve or reject particular study.

29. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

30. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained.

31. The Ethics Committee shall allow any officer authorized by the Central Licencing Authority to enter, with or without prior notice, to inspect the premises, any record, or any documents related to clinical trial, furnish information to any query raised by such authorized person, in relation to the conduct of clinical trial and to verify compliance with the requirements of these rules, Good Clinical Practices Guidelines and other applicable regulations for safeguarding the rights, safety and well-being of trial subjects.

32. Where Central Licencing Authority is of the opinion that Ethics Committee fails to comply with any provision of the Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019, it may issue show cause notice to such Ethics Committee specifying therein such non-compliances and the period within which reply shall be furnished by such Ethics Committee. After consideration of the facts and reply given by the Ethics Committee, the Central Licencing Authority may take one or more actions specified under provision of Rule 14, Chapter III of New Drugs and Clinical Trials Rules, 2019.



सत्यमेव जयते


Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Ethics Committee Registration Division)

FDA Bhawan, Kotla Road,
New Delhi - 110002, India
Dated: 13-Jun-2022

Composition of the Ethics Committee:-

Sr. No.	Name of Member	Qualification	Role/Designation in Ethics Committee
1.	Dr. Pratibha Pereira	MBBS (MD - General Medicine)	Clinician
2.	Ms. H S Sandhya	BA (BA)	Social Scientist
3.	Dr. Sri Harsha Chalasani	BSc (M.Pharm, P.hD)	Scientific Member
4.	Mr. Palaksha Palaksha	B.Sc. (LLB)	Legal Expert
5.	Dr. K M Srinath	MBBS (MD-Internal Medicine)	Clinician
6.	Dr. Sathyanarayana Mamatha	BA (B.Ed, PhD)	Lay Person
7.	Dr. C Prathima	MBBS (MD-Pharmacology)	Member Secretary
8.	Dr. H L Kalabharathi	MBBS (MD-Pharmacology)	Medical Scientist
9.	Dr. Smitha Rani	MBBS (MD-Forensic Medicine)	Medical Scientist
10.	Ms. Smt Sudha Phaneesh	BA (B.Ed. PhD)	Social Scientist
11.	Mr. RS Nagaraj	BSc (MBA)	Lay Person
12.	Mr. C K Rudramurthy	B.A (LLB)	Legal Expert
13.	Dr. M Srinivasa	MBBS (MD-General Medicine)	Chair Person

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROL ORGANIZATION (INDIA), pseudonym=112046e34e21727bacb25574872e135027b78e35c53d9cb5b58748
VENUGOPAL G SOMANI
Drugs Control General Authority
serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.06.13 18:21:36 +05'30'



Government of India
 Ministry of Health & Family Welfare
 Directorate General of Health Services
 Office of Drugs Controller General (India)
 Central Drugs Standard Control Organization

FDA Bhawan, Kotla Road,
 New Delhi - 110 002, India
 Dated: 06/04/2018

To

The Chairman
Institutional Ethics Committee,
JSS Medical College & Hospital,
3rd Floor, JSS Medical College,
Mysore-570015, Karnataka

SECRETARY
 15/4/18

Subject: Ethics Committee Re-registration No. **ECR/387/Inst/KA/2013/RR-16** amendment to the composition of the Ethics Committee-regarding.


Sir/Madam,

Please refer to your application submitted to this Directorate for change in composition of the Re-registered Ethics Committee.

Based on the documents submitted by you, the composition of your Ethics Committee bearing Re-registration number **ECR/387/Inst/KA/2013/RR-16** dated **19.08.2016** valid until **10.06.2019** is hereby amended as follows, with all conditions of the Re-registration Certificate initially granted to you, remaining the same:-

Sr. No.	Name of member	Qualification	Role/Designation in Ethics Committee
1.	Dr. M. Premanth	MBBS, MD (General Medicine)	Chairman
2.	Dr. R.N. Suresha	MD (Pharmacology)	Member Secretary
3.	Dr. H. Basavana Gowdappa	MBBS, MD (General Medicine)	Clinician
4.	Dr. M. Guruswamy	MS, ENT	Clinician
5.	Dr. Prathiba Pareira	MD (General Medicine)	Clinician
6.	Dr. R. Rajalakshmi	MD (Physiology)	Basic Medical Scientist
7.	Sri. R.S. Nagaraj	B.Sc, MBA	Lay Person
8.	Sri. Nagendra Murthy M.P	B.Com, LLM, M.Phil	Legal Expert
9.	Smt. Sudhaphaneesh	MA, B.Ed, PhD	Social Scientist
10.	Dr. Madan Ramesh	M.Pharm, PhD	Scientific Member

Yours faithfully


Dr. S. ESWARA REDDY
 (Dr. S. Eswara Reddy)
 Drugs Controller General (India)
 & Licensing Authority
 Ministry of Health and Family Welfare
 FDA Bhawan, Kotla Road, I.T.O.
 New Delhi-110002



सत्यमेव जयते

File No. EC/19/000060
Government of India
Ministry of Health & Family Welfare
Directorate General of Health Services
Office of Drugs Controller General (India)
Central Drugs Standard Control Organization

FDA Bhawan, Kotla Road,
New Delhi - 110002, India
Dated: 13-Jun-2019

To

The Chairman
Institutional Ethics Committee JSS Medical College
JSS Medical College and Hospital
Sri Shivarathreeswara Nagar Mysore Mysore Mysuru
(Mysore) Karnataka - 570015 India



Subject: Ethics Committee Re-Registration No. ECR/387/Inst/KA/2013/RR-19 issued under Rule 122DD of the Drugs & Cosmetics Rules 1945.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/2547 dated 09-Mar-2019 submitted to this Directorate for the Re-Registration of Ethics Committee.

Your Ethics Committee is hereby re-registered under Rule 122DD vide Registration No. ECR/387/Inst/KA/2013/RR-19 with the following composition and all the condition mentioned under the Registration certificate issued to you.

Sr. No.	Name of Member	Qualification	Role/Designation in Ethics Committee
1	Mr. Nagendra Murthy MP	LLB (Master of Laws (LL.M.))	Legal Expert
2	Dr. Prathiba Pareira	MBBS (MD - General Medicine)	Clinician
3	Dr. Prathima C	MBBS (MD-Pharmacology)	Basic Medical Scientist
4	Dr. Srinivasa M	MBBS (Medicine)	Chair Person
5	Dr. Suresha R N	MBBS (Pharmacology)	Member Secretary
6	Dr. Ramesh M	Dpharm (Mpharm)	Scientific Member
7	Mr. Palaksha P	LLB (LLB)	Legal Expert
8	Ms. Y.T. Madhuri Thatachari	BA (MA Geography)	Social Scientist
9	Dr. Savitha L	BA (M.Ed)	Lay Person
10	Dr. Suchitha S	MBBS (MD pathology)	Basic Medical Scientist
11	Dr. Vikram Patil	MBBS (DNB)	Clinician
12	Ms. Sudha Phaneesh	BA (B.Ed., Ph.D)	Social Scientist
13	Mr. Nagaraj RS	BSc (MBA)	Lay Person

Forwarded to Member Secretary

PRINCIPAL
JSS Medical College
S.S. Nagar,
Mysore

S ESWARA REDDY
(Dr. S. Eswara Reddy)
Drugs Controller General (I) &
Licensing Authority




सत्यमेव जयते

Government of India
Ministry of Health & Family Welfare,
Directorate General of Health Services
Office of Drugs Controller General (India)
Central Drugs Standard Control Organization

FDA Bhawan, Kotla Road,
New Delhi - 110002, India
Dated: 13-Jun-2019

To

The Chairman
Institutional Ethics Committee JSS Medical College
JSS Medical College and Hospital
Sri Shivarathreeshwara Nagar Mysore Mysore Mysuru
(Mysore) Karnataka - 570015 India



stima

Subject: Ethics Committee Re-Registration No. ECR/387/Inst/KA/2013/RR-19 issued under Rule 122DD of the Drugs & Cosmetics Rules 1945.

Sir/Madam,

Please refer to your application no. EC/RENEW/INST/2019/2547 dated 09-Mar-2019 submitted to this Directorate for the Re-Registration of Ethics Committee

Based on the documents submitted by you, this office hereby Re-Registers the Institutional Ethics Committee JSS Medical College situated at JSS Medical College and Hospital Sri Shivarathreeshwara Nagar Mysore Mysore Mysuru (Mysore) Karnataka - 570015 with Re-Registration Number ECR/387/Inst/KA/2013/RR-19 as per the provisions of Rule 122DD of the Drugs and Cosmetics Rules, 1945 subject to the following conditions:

1. The re-registration shall be in force from 11-Jun-2019 to 10-Jun-2022, unless it is sooner suspended or cancelled.
2. This registration is subject to the conditions specified under the New Drugs and Clinical Trials Rules, 2019.
3. The Ethics Committee shall review and accord its approval to a clinical trial and also carry ongoing review of the trial at appropriate intervals as specified in Chapter III of the New Drugs and Clinical Trials Rules, 2019 and the Good Clinical Practice Guidelines for Clinical Trials in India and other applicable regulatory requirements for safeguarding the rights, safety and well-being of the trial subjects.
4. In the case of any serious adverse event occurring to the clinical trial subjects during the clinical trial, the Ethics Committee shall analyze and forward its opinion as per procedures specified under Chapter VI of New Drugs and Clinical Trials Rules, 2019.
5. The Ethics Committee shall allow inspectors or officials authorized by the Central Drugs Standard Control Organization to enter its premises to inspect any record, data or any document related to clinical trial and provide adequate replies to any query raised by such inspectors or officials, as the case may be, in relation to the conduct of clinical trial.
6. The licensing authority shall be informed in writing in case of any change in the membership or the constitution of the ethics committee takes place.
7. All the records of the ethics committee shall be safely maintained after the completion or termination of the study for not less than five years from the date of completion or termination of the trial (Both in hard and soft copies).
8. If the Ethics Committee fails to comply with any of the conditions of registration, the Licensing Authority may,

Forwarded to Member Secretary
PRINCIPAL
JSS Medical College
[Signature] 29/6/19

after giving an opportunity to show cause why such an order should not be passed, by an order in writing stating the reasons therefore, suspend or cancel the registration of the Ethics Committee for such period as considered necessary.

9. Ethics Committee shall consist of not less than seven members and is subject to a maximum of 15. One among its members, who is from outside the institute, shall be appointed as chairman, one member as a Member Secretary and rest of the members shall be from Medical, Scientific, Non-Medical and Non-scientific fields including lay public and one woman member.

10. The Ethics committee shall consist of at least 50% members who are not affiliated with the Institute or organization in which such committee is constituted.

11. The committee shall include at least one member whose primary area of interest or specialization is Non-scientific and at least one member who is independent of the institution besides; there should be appropriate gender representation on the Ethics Committee.

12. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.

13. Members should be conversant with the provisions of clinical trials, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

14. For review of each protocol the quorum of Ethics Committee shall be at least five members with the following representations:

- I. Basic medical scientist (preferably one pharmacologist)
- II. Clinician
- III. Legal expert
- IV. Social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person.
- V. Lay person from community

15. The members representing medical scientist and clinicians should have Post graduate qualification and adequate experience in their respective fields and aware of their role and responsibilities as committee members.

16. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.

17. There should be no conflict of interest. The members shall voluntarily withdraw from the Ethics Committee meeting while making a decision on an application which evokes a conflict of interest which may be indicated in writing to the Chairman prior to the review and be recorded so in the minutes. All members shall sign a declaration on conflict of interest.

18. Subject experts or other experts may be invited to the meetings for their advice. But no such expert shall have voting rights.

19. This certificate is issued to you on the basis of declaration/submission by you that yours is an Institution and re-registration is sought for Institutional Ethics Committee.

20. Funding mechanism for the Ethics Committee to support their operations should be designed to ensure that the committee and their members have no financial incentive to approve or reject particular studies.

21. SOP's for funding of the Ethics committee in order to support their operations must be maintained. The records of income & expenditure of Ethics Committee shall be maintained for review and inspection.

22. The Chairman of Ethics Committee shall enter into MOU with head of institution, that necessary support and facilities and independence will be provided to Ethics Committee and their records will be maintained as long as required.

23. Ethics Committee may undertake the review and monitoring of clinical trial protocols of other investigator(s) and site(s) who do not have their IEC, subject to the condition that the other sites are within the loco- regional and community settings similar to that of the registered Ethics committee. The approving ethics committee must be willing to accept their responsibilities for the study at such trial site(s) and the trial site(s) willing to accept such an arrangement.

24. Ethics Committee shall review and approve the suitability of the investigator and trial site for the proposed trial. The ethics committee shall undertake proper causality assessment of SAE's with the help of subject experts where required, for deciding relatedness and compensation, as per condition no (4) mentioned above.

**S ESWARA
REDDY**
(Dr. S. Eswara Reddy)
Drugs Controller General (I) &
Licensing Authority

Digitally signed by S ESWARA REDDY
DN: cn=IN-CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION,
o=3.4.2019-revwebd03e6c0eae0d0d8a1e132
e09a6fa3a0c0a4e7e7e0e0d0b3e781e
144, ou=DRUGS, c=IN
serial=0d0e110002, st=Delhi, cn=S
ESWARA REDDY
Date: 2019.06.13 17:31:12 +05'30



Government of India
Ministry of Health & Family Welfare
Directorate General of Health Services
Office of Drugs Controller General (India)
Central Drugs Standard Control Organization

FDA Bhawan, Kotla Road,
New Delhi - 110 002, India

Dated: 19/08/2016

To

**The Chairman,
Institutional Ethics Committee,
JSS Medical College & Hospital,
3rd Floor, JSS Medical College,
Mysore-570015, Karnataka**



Stano
ec
2/8

SUB:- Ethics Committee Re-Registration No. **ECR/387/Inst/KA/2013/RR-16** issued under Rule 122DD of the Drugs & Cosmetics Rules 1945.


Sir/Madam,

Please refer to your application no. JSSMC/IEC/Registration/6924/2015-16 dated 10.03.2016 submitted to this office for the Re-Registration of Ethics Committee.

Based on the documents submitted by you, this office hereby re-registers the **INSTITUTIONAL ETHICS COMMITTEE** situated at **JSS MEDICAL COLLEGE & HOSPITAL, 3rd FLOOR, JSS MEDICAL COLLEGE, MYSORE-570015, KARNATAKA, INDIA** with Registration Number **ECR/387/Inst/KA/2013/RR-16** as per the provisions of Rule 122DD of the Drugs and Cosmetics Rules, 1945 subject to the following conditions:

1. The registration shall be in force from 11.06.2016 to 10.06.2019, unless it is sooner suspended or cancelled.
2. This registration is subject to the conditions specified under Rule 122DD and Appendix VIII of Schedule-Y of Drugs and Cosmetics Act, 1940 and Rules 1945.
3. The Ethics Committee shall review and accord its approval to a clinical trial at appropriate intervals as specified in Schedule Y and the Good Clinical Practice Guidelines for Clinical Trials in India and other applicable regulatory requirements for safeguarding the rights, safety and well-being of the trial subjects.
4. In the case of any serious adverse event occurring to the clinical trial subjects during the clinical trial, the Ethics Committee shall analyze and forward its opinion as per procedures specified under APPENDIX XII of Schedule Y.
5. The Ethics Committee shall allow inspectors or officials authorized by the Central Drugs Standard Control Organization to enter its premises to inspect any record, data or any document related to clinical trial and provide adequate replies to any query raised by such inspectors or officials, as the case may be, in relation to the conduct of clinical trial.
6. The licensing authority shall be informed in writing in case of any change in the membership or the constitution of the ethics committee takes place.
7. All the records of the ethics committee shall be safely maintained after the completion or termination of the study for not less than five years from the date of completion or termination of the trial (Both in hard and soft copies).

8. If the Ethics Committee fails to comply with any of the conditions of registration, the Licensing Authority may, after giving an opportunity to show cause why such an order should not be passed, by an order in writing stating the reasons therefore, suspend or cancel the registration of the Ethics Committee for such period as considered necessary.
9. Ethics Committee shall consist of not less than seven members and is subject to a maximum of 15. One among its members, who is from outside the institute, shall be appointed as chairman, one member as a Member Secretary and rest of the members shall be from Medical, Scientific, Non-Medical and Non-scientific fields including lay public.
10. The committee shall include at least one member whose primary area of interest or specialization is Non-scientific and at least one member who is independent of the institution besides; there should be appropriate gender representation on the Ethics Committee.
11. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.
12. Members should be conversant with the provisions of clinical trials under this Schedule, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.
13. For review of each protocol the quorum of Ethics Committee shall be at least five members with the following representations:
 - I. Basic medical scientist (preferably one pharmacologist)
 - II. Clinician
 - III. Legal expert
 - IV. Social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person.
 - V. Lay person from community
14. The members representing medical scientist and clinicians should have Post graduate qualification and adequate experience in their respective fields and aware of their role and responsibilities as committee members.
15. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.
16. There should be no conflict of interest. The members shall voluntarily withdraw from the Ethics Committee meeting while making a decision on an application which evokes a conflict of interest which may be indicated in writing to the Chairman prior to the review and be recorded so in the minutes. All members shall sign a declaration on conflict of interest.
17. Subject experts or other experts may be invited to the meetings for their advice. But no such expert shall have voting rights.
18. This certificate is issued to you on the basis of declaration/submission by you that yours is an Institution and re-registration is sought for Institutional Ethics Committee.


V. G. S.
(Dr. V. G. Somani)
Joint Drugs Controller (I) & Licensing Authority
Dr. V. G. SOMANI
Joint Drugs Controller (I) & Licensing Authority
Directorate General of Health Services
FOA Bhawan, Kolla Road, New Delhi-110002



Government of India
Ministry of Health & Family Welfare
Directorate General of Health Services
Office of Drugs Controller General (India)
Central Drugs Standard Control Organization

FDA Bhawan, Kotla Road,
New Delhi - 110 002, India
Dated: 19/08/2016

To,

**The Chairman,
Institutional Ethics Committee,
JSS Medical College & Hospital,
3rd Floor, JSS Medical College,
Mysore-570015, Karnataka**

SUB:- Ethics Committee Re-Registration No. **ECR/387/Inst/KA/2013/RR-16** issued under Rule 122DD of the Drugs & Cosmetics Rules 1945.

Sir/Madam,

Please refer to your application no. JSSMC/IEC/Registration/6924/2015-16 dated 10.03.2016 submitted to this office for the Re-Registration of Ethics Committee.

Your Ethics Committee is hereby re-registered under Rule 122DD vide Registration No. **ECR/387/Inst/KA/2013/RR-16** with the following composition and all the condition mentioned under the Registration certificate issued to you.

Sr. No.	Name of member	Qualification	Role/Designation in Ethics Committee
1.	Dr. M. Premanth	MBBS, MD (General Medicine)	Chairman
2.	Dr. R.N. Suresha	MD (Pharmacology)	Member Secretary
3.	Dr. H. Basavana Gowdappa	MBBS, MD (General Medicine)	Clinician
4.	Dr. M. Guruswamy	MS, ENT	Clinician
5.	Dr. R. Rajalakshmi	MD (Physiology)	Basic Medical Scientist
6.	Sri. R.S. Nagaraj	B.Sc, MBA	Lay Person
7.	Sri. Nagendra Murthy M.P	B.Com, LLM, M.Phil	Legal Expert
8.	Smt. Sudhaphaneesh	MA, B.Ed, PhD	Social Scientist
9.	Dr. Madan Ramesh	M.Pharm, PhD	Scientific Member

(Dr. V. G. Somani)

Joint Drugs Controller (I) & Licensing Authority

Dr. V. G. SOMANI
Joint Drugs Controller-(In-charge)
Directorate General of Health Services
FDA Bhawan, Kotla Road, New Delhi-110002

From:

o/ The Drugs Controller General (India)
Directorate General of Health Services



FDA Bhawan, Kotla Road,
New Delhi - 110 002

Dated:

12 JUN 2013

To

The Chairman,
Institutional Ethics Committee,
JSS Medical College & Hospital,
3rd Floor, JSS Medical College,
Mysore, Karnataka

SUB: - Ethics Committee Registration No. ECR/387/Inst/KA/2013 issued under Rule 122DD of the Drugs & Cosmetics Rules 1945.

Dear Sir

Please refer to your application no. Nil, dated 16 May 2013 submitted to this office for the Registration of Ethics Committee.

Based on the documents submitted by you, this office hereby registers the **INSTITUTIONAL ETHICS COMMITTEE**, situated at **JSS Medical College & Hospital, 3rd Floor, JSS Medical College, Mysore, Karnataka** with Registration number **ECR/387/Inst/KA/2013** as per the provisions of Rule 122DD of the Drugs and Cosmetics Rules, 1945 subject to the following conditions:

1. This Registration is subject to the conditions specified under Rule 122DD and Appendix VIII of Schedule-Y of Drugs and Cosmetics Act, 1940 and Rules 1945.
2. The Ethics Committee shall review and accord its approval to a clinical trial at appropriate intervals as specified in Schedule Y and the Good Clinical Practice Guidelines for Clinical Trials in India and other applicable regulatory requirements for safeguarding the rights, safety and well being of the trial subjects.
3. In the case of any serious adverse event occurring to the clinical trial subjects during the clinical trial, the Ethics Committee shall analyze and forward its opinion as per procedures specified under APPENDIX XII of Schedule Y.
4. The Ethics Committee shall allow inspectors or officials authorized by the Central Drugs Standard Control Organization to enter its premises to inspect any record, data or any document related to clinical trial and provide adequate replies to any query raised by such inspectors or officials, as the case may be, in relation to the conduct of clinical trial.
5. The licensing authority shall be informed in writing in case of any change in the membership or the constitution of the ethics committee takes place.
6. All the records of the ethics committee shall be safely maintained after the completion or termination of the study for not less than five years from the date of completion or termination of the trial (Both in hard and soft copies).

(Cont...)


Dr. General of Health Services
Deputy Drugs Controller (II)
Central Drugs Standard Control Organization
FDA Bhawan, Kotla Road, New Delhi-110002

7. If the Ethics Committee fails to comply with any of the conditions of registration, the Licensing Authority may, after giving an opportunity to show cause why such an order should not be passed, by an order in writing stating the reasons therefore, suspend or cancel the registration of the Ethics Committee for such period as considered necessary.
8. This registration shall be in force for a period of three years from the date of issue, unless it is sooner suspended or cancelled.
9. Ethics Committee shall consist of not less than seven members and is subject to a maximum of 15. One among its members, who is from outside the institute, shall be appointed as chairman, one member as a Member Secretary and rest of the members shall be from Medical, Scientific, Non Medical and Non-scientific fields including lay public
10. The committee shall include at least one member whose primary area of interest or specialization is Non-scientific and at least one member who is independent of the institution besides; there should be appropriate gender representation on the Ethics Committee.
11. The Ethics committee can have as its members, individuals from other Institutions or Communities, if required.
12. Members should be conversant with the provisions of clinical trials under the Schedule Y, Good Clinical Practice Guidelines for clinical trials in India and other regulatory requirements to safeguard the rights, safety and well-being of the trial subjects.

For review of each protocol the quorum of Ethics Committee shall be at least five members with the following representations:

- I. Basic medical scientist (preferably one pharmacologist)
 - II. Clinician
 - III. Legal expert
 - IV. Social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian or a similar person.
 - V. Lay person from community
13. The members representing medical scientist and clinicians should have Post graduate qualification and adequate experience in their respective fields and aware of their role and responsibilities as committee members.
 14. As far as possible, based on the requirement of research area such as HIV, Genetic disorder, etc., specific patient group may also be represented in the Ethics Committee.
 15. There should be no conflict of interest. The members shall voluntarily withdraw from the Ethics Committee meeting while making a decision on an application which evokes a conflict of interest which may be indicated in writing to the Chairman prior to the review and be recorded so in the minutes. All members shall sign a declaration on conflict of interest.
 16. Subject experts or other experts may be invited to the meetings for their advice. But no such expert shall have voting rights.
 17. This certificate is issued to you on the basis of declaration/ submission by you that yours is an institution and registration is sought for institutional Ethics Committee

Yours Faithfully


12/6/2013
(A. Visala)

Deputy Drugs Controller (I) & Licensing Authority

A. Visala
Deputy Drugs Controller (I)
Dts. General of Health Services
Central Drugs Standard Control Organisation
FDA Bhawan, Kala Road, New Delhi-110002

File No. ECR/784/JSS/Inst/Kar/2013
Directorate General of Health Services
Office of Drugs Controller General (India)

FDA Bhawan, Kotla Road,
New Delhi – 110 002, India
Dated:

12 JUN 2013

To

The Chairman,
Ethics Committee,
JSS Medical College & Hospital,
3rd Floor, JSS Medical College,
Mysore, Karnataka

SUB: - Application for Registration of Ethics Committee

Dear Sir

Please refer to your application no. Nil, dated 16 May 2013 submitted to this office for the Registration of Ethics Committee.

This is to inform that your ethics committee has been registered with ECR/387/Inst/KA/2013 subject to the condition that you should inform the designation and roles of each of the members in accordance with GSR 72(E)ie Rule 122DD of Drugs and Cosmetics Rules 1945. You are required to submit the above information to this directorate within 10 days from the receipt of this letter.

Yours faithfully,


12/6/2013

(A. Visala)

Deputy Drugs Controller (I)